Stock LXRX LEXICON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Lexicon Pharmaceuticals, Inc.

Equities

LXRX

US5288723027

Real-time Estimate Cboe BZX
Other stock markets
 10:20:26 2024-04-19 am EDT 		5-day change 1st Jan Change
1.655 USD +1.53% Intraday chart for Lexicon Pharmaceuticals, Inc. -15.99% +8.17%
Mar. 25 Lexicon Pharmaceuticals Files Prospectus for Secondary Offering MT
Mar. 12 Lexicon Pharmaceuticals Shares Decline After Analysis Finds Similar Effect of Sotagliflozin in Type 1 Diabatic Patients MT

Evolution of the average Target Price on Lexicon Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

5c.wV66Fh7ipPl5XhIiu2o3mroXKaxXAVPFGpNnz55_NeI.lw7gf2-D585JZ1x7yzUBr91tTcg2RRGBddYJnq8-fZu0P4tkearnoBUmRw~fa82062a3e9562e261e0afc53a5321ef

Analyst Recommendations on Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Files Prospectus for Secondary Offering MT
North American Morning Briefing: Treasury Yields Dive as Rate-Rise Fears Ease DJ
Citigroup Adjusts Price Target on Lexicon Pharmaceuticals to $8 From $6, Keeps Buy Rating MT
Jefferies Starts Lexicon Pharmaceuticals at Hold With $3 Price Target MT
Lexicon Pharmaceuticals Shares Rise After Piper Sandler Initiates Coverage MT
Piper Sandler Starts Lexicon Pharmaceuticals at Overweight With $10 Price Target MT
Citigroup Adjusts Lexicon Pharmaceuticals' Price Target to $20 from $18, Keeps Buy Rating MT
LEXICON PHARMACEUTICALS : Wedbush Suspended Coverage on Lexicon Pharmaceuticals MT
LEXICON PHARMACEUTICALS : Citigroup Adjusts Price Target on Lexicon Pharmaceuticals to $20 From $13, Maintains Buy Rating MT
LEXICON PHARMACEUTICALS : Wedbush Cuts Lexicon Pharmaceuticals' PT to $5 From $8 on Adjusted Timelines for Sotaglifozin/Heart Failure, Xermelo/BTC; Neutral Rating Kept MT
LEXICON PHARMACEUTICALS : JPMorgan Upgrades Lexicon Pharmaceuticals to Neutral From Underweight; Price Target is $7 MT
LEXICON PHARMACEUTICALS : Wedbush Cuts Lexicon Pharmaceuticals to Neutral From Outperform Pending Clarity on Sotagliflozin Partnership; PT to $8 From $2 MT
LEXICON PHARMACEUTICALS : Citigroup Upgrades Lexicon Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $6 From $2.10 MT
LEXICON PHARMACEUTICALS : Gabelli Upgrades Lexicon Pharmaceuticals to Buy From Hold MT
LEXICON PHARMACEUTICALS : Wedbush Adjusts Price Target on Lexicon Pharmaceuticals to $2 From $3, Keeps Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.63 USD
Average target price
5.5 USD
Spread / Average Target
+237.42%
High Price Target
10 USD
Spread / Highest target
+513.50%
Low Price Target
2.5 USD
Spread / Lowest Target
+53.37%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Lexicon Pharmaceuticals, Inc.

Citigroup
Jefferies & Co.
Piper Sandler
Wedbush
J.P. Morgan Chase

Ratings for Lexicon Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. LXRX Stock
  4. Consensus Lexicon Pharmaceuticals, Inc.